Skip to main content

Eiger BioPharmaceuticals reports disappointing study results

Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) reported disappointing results from a Phase 2 LIBERTY study in pulmonary arterial hypertension sending the stock price crashing $7.90 to close at $8.10.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.